Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 9/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110168 | 0.89 | LMNA (0.63) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8599201 | 0.85 | LMNA (0.68) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2096058 | 0.81 | LMNA (0.61) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1734928 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1532839 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1437457 | 0.79 | MAOB (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1744108 | 0.79 | MAOB (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7779413 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2900304 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2390178 | 0.79 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-2452944-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1501819-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1501819-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091239-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-4751316-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | LMNA 3511/4885CYP1A2 67/4885PTGS1 1149/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | LMNA 3520/4885CYP1A2 45/4885PTGS1 800/4885 |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | S1PR3, S1PR1, S1PR2 | LMNA 4473/4885CYP1A2 2584/4885PTGS1 268/4885 |
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | LMNA 873/4885CYP1A2 1878/4885PTGS1 1975/4885 |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | LMNA 3640/4885CYP1A2 53/4885PTGS1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.